Targeted Therapy for METex14-Mutated NSCLC

An overview of recent FDA breakthrough therapy designations for the MET inhibitors capmatinib and tepotinib as new treatment options for patients with MET exon 14–mutated non–small cell lung cancer.

Read the full article here

Related Articles